Survival effect of adjuvant therapy in stage II-III endometrial cancer: interaction to malignant peritoneal cytology

Abstract

Objectives: To examine the survival effect of adjuvant therapy in stage II-III endometrial cancer based on peritoneal cytology results. Methods: The Surveillance, Epidemiology, and End Results Program was retrospectively queried to examine 7,467 women with stage II-III endometrial cancer who underwent hysterectomy with available peritoneal cytology results from 2010-2016. Propensity score inverse probability of treatment weighting was used to assess the survival effect of malignant peritoneal cytology, and Cox proportional hazard regression model was fitted to assess the association between adjuvant therapy and all-cause mortality stratified by peritoneal cytology results. Results: Malignant peritoneal cytology was reported in 1,662 (22.3%) women, and was associated with non-endometrioid histology, higher tumor stage, and nodal metastasis in multivariable analysis (all, P Download : Download high-res image (79KB) Download : Download full-size image Conclusions: Malignant peritoneal cytology is prevalent and prognostic in stage II-III endometrial cancer. This study found that the benefit of adjuvant therapy for women with stage II-III endometrial cancer differed depending on the status of peritoneal cytology.